Non-muscle-invasive bladder cancer

Solicite una Consulta

Survival rates

Survival rates describe what has happened in large groups of people. Survival rates cannot predict exactly what will happen to you.

For high-grade NMIBC, cancer-specific survival is about 70% to 85% at 10 years. Survival is higher for low-grade disease. Cancer-specific survival is the percentage of people who have not died from the cancer during a set time.

The National Cancer Institute reports a five-year relative survival rate of 97% for carcinoma in situ of the bladder alone.

Broader survival categories, such as localized bladder cancer, are not the same as Ta, T1 or NMIBC risk groups.

Survival statistics are based on people treated in earlier years. So they may not fully show the effects of newer treatments.

Solicite una consulta
StagesMédicos y departamentos
Sept. 10, 2026
  1. Flaig TW, et al. Bladder cancer, version 1.2026, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2026; doi:10.6004/jnccn.2026.0022.
  2. Holzbeierlein JM, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. Journal of Urology. 2024; doi:10.1097/JU.0000000000003846.
  3. Bladder cancer stages. National Cancer Institute. https://www.cancer.gov/types/bladder/stages. Accessed Aug. 27, 2026.
  4. Bladder cancer diagnosis. National Cancer Institute. https://www.cancer.gov/types/bladder/diagnosis. Accessed Aug. 27, 2026.
  5. Treatment of bladder cancer by stage. National Cancer Institute. https://www.cancer.gov/types/bladder/treatment/by-stage. Accessed Aug. 27, 2026.
  6. Bladder cancer — Cancer stat facts. Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed Aug. 27, 2026.
  7. Narayan VM, et al. Efficacy of intravesical nadofaragene firadenovec for patients with bacillus Calmette-Guérin-unresponsive nonmuscle-invasive bladder cancer: 5-year follow-up from a phase 3 trial. Journal of Urology. 2024; doi:10.1097/JU.0000000000004020.
  8. Necchi A, et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial. The Lancet Oncology. 2024; doi:10.1016/S1470-2045(24)00178-5.
  9. Guerrero-Ramos F, et al. Predicting recurrence and progression in patients with non-muscle-invasive bladder cancer: Systematic review on the performance of risk stratification models. Bladder Cancer. 2022; doi:10.3233/BLC-220055.
  10. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). European Association of Urology. https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer. Accessed Aug. 27, 2026.
  11. Bladder cancer treatment (PDQ) — Health professional version. National Cancer Institute. https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq. Accessed Aug. 12, 2026.
  12. Bladder cancer prognosis and survival rates. National Cancer Institute. https://www.cancer.gov/types/bladder/survival. Accessed Aug. 12, 2026.

Non-muscle-invasive bladder cancer